Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. AAPL
3. TTAN
4. CHYM
5. USO
6. IRT
7. QCOM
8. ASO
9. LAES
10. NTHI

Go back to Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy

Sarepta Therapeutics (SRPT) PT Raised to $96 at H.C. Wainwright

May 7, 2018 8:17 AM EDT

H.C. Wainwright raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $96.00 (from $90.00) while maintaining a Buy rating following the company's 1Q. During its 1Q18 corporate update, Sarepta also disclosed an exclusive collaboration and investment in Myonexus Therapeutics.

The alliance,... More